Ensartinib
Ensartinib, sold under the brand name Ensacove, is an anti-cancer medication used for the treatment of non-small cell lung cancer. Ensartinib is an Anaplastic lymphoma kinase inhibitor used as the salt ensartinib hydrochloride. It is taken by mouth.
The most common adverse reactions include rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.
Ensartinib was approved for medical use in the United States in December 2024.
Medical uses
Ensartinib is indicated for the treatment of adults with anaplastic lymphoma kinase -positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.History
Efficacy was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial in 290 participants with locally advanced or metastatic ALK-positive non-small cell lung cancer who had not previously received an ALK-targeted therapy. Participants were randomized 1:1 to receive ensartinib or crizotinib.Society and culture
Legal status
Ensartinib was approved for medical use in the United States in December 2024.Names
Ensartinib is the international nonproprietary name.Ensartinib is sold under the brand name Ensacove.